Benzene Ring Containing Patents (Class 514/107)
  • Patent number: 10174061
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: January 8, 2019
    Assignee: ABBVIE INC.
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Brian P. Enright, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
  • Patent number: 9526739
    Abstract: Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogues for treatment of heart failure has been expanded.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: December 27, 2016
    Assignees: UNIVERSITY OF CONNECTICUT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Bruce Liang, Kenneth A. Jacobson
  • Patent number: 9446059
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: September 20, 2016
    Assignee: AbbVie Inc.
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
  • Patent number: 9173946
    Abstract: The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: or a pharmaceutically-acceptable salt thereof, a method for producing the same, pharmaceutical compositions containing the same, and the use thereof as a medicament, as well as a compound of formula (II) below: or a pharmaceutically-acceptable salt thereof, and the use thereof for producing a vectorized molecule of therapeutic or diagnostic purpose.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: November 3, 2015
    Assignee: ATLANTHERA
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot
  • Patent number: 9006387
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: April 14, 2015
    Assignee: AbbVie Inc.
    Inventors: Rolf Wagner, John K. Pratt, Dachun Liu, Michael D. Tufano, David A. DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi, Yi Gao, Allan C. Krueger
  • Patent number: 8962600
    Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: February 24, 2015
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Balaraman Kalyanaraman, Joy Joseph, Anumantha Kanthasamy
  • Publication number: 20150037306
    Abstract: The present invention relates to a method for controlling insects comprising the steps of preparing a tankmix by mixing a larvicide and a liquid adjuvant, wherein the adjuvant is essentially free of the larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic solvent; and applying the tankmix on a water surface. The invention further relates to a liquid adjuvant for preparing a larvicidal tankmix, wherein the adjuvant is essentially free of a larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic solvent. Finally, it relates to a method for preparing said adjuvant, comprising mixing the polyorganosiloxan and the synthetic organic solvent.
    Type: Application
    Filed: January 21, 2013
    Publication date: February 5, 2015
    Applicant: BASF SE
    Inventors: Claude Taranta, Helmut Mueller, Susanne Stutz, Egon Weinmueller, James W. Austin
  • Publication number: 20150037256
    Abstract: The present invention relates to the use of silver(l) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer.
    Type: Application
    Filed: December 6, 2012
    Publication date: February 5, 2015
    Inventors: Reinout Meijboom, Marianne Jacqueline Cronje
  • Publication number: 20150025042
    Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 16, 2013
    Publication date: January 22, 2015
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Shoujun Chen, Keizo Koya, Zachary Demko, Lijun Sun
  • Patent number: 8937150
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: January 20, 2015
    Assignee: AbbVie Inc.
    Inventors: David A. DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, Allan C. Krueger, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Yi Gao, Dachun Liu, John K. Pratt, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, Rolf Wagner, Michael D. Tufano, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi, William A. Carroll
  • Patent number: 8933058
    Abstract: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: January 13, 2015
    Assignee: Nanyang Technological University
    Inventors: Subramanian Venkatraman, Say Chye Joachim Loo
  • Publication number: 20150005261
    Abstract: The invention provides methods for treating fibrosis, as well as methods for modulating mitochondrial peroxide production in a cell, and methods for modulating the import of Rac1 into the mitochondria of a cell.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 1, 2015
    Applicant: University of Iowa Research Foundation
    Inventors: Raymond J. Hohl, A. Brent Carter
  • Patent number: 8921514
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: December 30, 2014
    Assignee: AbbVie Inc.
    Inventors: David A. DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, Allan C. Krueger, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Yi Gao, Dachun Liu, John K. Pratt, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, Rolf Wagner, Michael D. Tufano, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi, William A. Carroll
  • Publication number: 20140371177
    Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
  • Patent number: 8895056
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 25, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Stephen D. Pacetti, Paul M. Consigny, Ronald W. Heil, Jr., Florian Niklas Ludwig, Dariush Davalian, Li Zhao, Irina Astafieva, Jinping Wan, Fozan El-Nounou, Katsuyuki Murase, Syed F. A. Hossainy, Rachel Bright, Jeffrey Ellis
  • Patent number: 8883203
    Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 11, 2014
    Assignee: Merrion Research III Limited
    Inventor: Thomas W. I. Leonard
  • Publication number: 20140315834
    Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.
    Type: Application
    Filed: September 23, 2013
    Publication date: October 23, 2014
    Applicant: Medicon Pharmaceuticals, Inc.
    Inventor: Basil RIGAS
  • Patent number: 8791092
    Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: July 29, 2014
    Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs, Massachusetts Institute of Technology, Universitat Duisburg-Essen
    Inventors: Gal Bitan, Akila Shanmugam, Aleksey Lomakin, Thomas Schrader, Frank Gerrit Klarner, Peter Talbiersky, Jolanta Polkowska, Frank Bastkowski, Sharmistha Sinha, Sally Frautschy
  • Publication number: 20140205648
    Abstract: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 24, 2014
    Applicant: DePuy Synthes Products, LLC
    Inventor: Maria Maccecchini
  • Patent number: 8778914
    Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 15, 2014
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Katrin Hochdoerffer
  • Patent number: 8772268
    Abstract: Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 8, 2014
    Assignee: The Johns Hopkins University
    Inventors: Caren Laura Freel Meyers, Marie Webster
  • Patent number: 8765674
    Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 1, 2014
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
  • Patent number: 8754121
    Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: June 17, 2014
    Assignee: Academia Sinica
    Inventors: Lie-Fen Shyur, Wen-Wan Chao, Ya-Wen Cheng
  • Patent number: 8748410
    Abstract: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: June 10, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Dai Yamanouchi, K. Craig Kent, Bo Liu
  • Publication number: 20140142065
    Abstract: Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 22, 2014
    Applicant: UNIVERSITY OF HONG KONG
    Inventors: Chi Ming CHE, Taotao ZOU
  • Publication number: 20140121185
    Abstract: Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.
    Type: Application
    Filed: September 23, 2013
    Publication date: May 1, 2014
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Publication number: 20140107078
    Abstract: The invention relates to hypophosphorous acid derivatives of formula (I) wherein —X is H or OH, —R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl group, one to four of R1-R5 being H and the others being selected in the group comprising -0-(CH2)n—COOH; —S—(CH2)n—COOH; —NH—(CH2)n—COOH; -0-(CH,R?)—COOH; —O—(CH2)n—OH; OR?, —R? being a C1-C3 alkyl radical; —OH; —COOH; halogen, particularly —F, —CI, —Br, —I, —CF3; —OCF3; —N02; —CH?CH—COOH; —(CH2)n—COOH; O—(CH2)n—P03H2; O—(CF2)n—P03H2; O—(CH2)n—S03H; O—(CH2)n—CONHOH; O—(CH2)n-tetrazol; O—(CH2)n-hydroxyisoxazol—n=1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers.
    Type: Application
    Filed: May 16, 2012
    Publication date: April 17, 2014
    Applicants: UNIVWESITE D"AUVERGNE, UNIVERSITE PARIS DESCARTES
    Inventors: Francine Acher, Jean-Philippe Pin, Cyril Goudet, Alain Eschalier, Jérôme Busserolles, Delphine Rigault, Isabelle Lemasson, Sara Cesarini, Brono Commare
  • Patent number: 8691938
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 8, 2014
    Assignee: AbbVie Inc.
    Inventors: David A. DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, Allan C. Krueger, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Yi Gao, Dachun Liu, John K. Pratt, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, Rolf Wagner, Michael D. Tufano, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi
  • Patent number: 8685936
    Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: April 1, 2014
    Assignee: Apogee Biotechnology Corporation
    Inventors: Charles D. Smith, Yan Zhuang, Lynn W. Maines
  • Publication number: 20140088044
    Abstract: The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and/or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 27, 2014
    Inventors: Basil Rigas, Jason B. Rigas
  • Publication number: 20140086843
    Abstract: The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: or a pharmaceutically-acceptable salt thereof, a method for producing the same, pharmaceutical compositions containing the same, and the use thereof as a medicament, as well as a compound of formula (II) below: or a pharmaceutically-acceptable salt thereof, and the use thereof for producing a vectorized molecule of therapeutic or diagnostic purpose.
    Type: Application
    Filed: March 28, 2012
    Publication date: March 27, 2014
    Applicant: ATLANTHERA
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot
  • Publication number: 20140057877
    Abstract: This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
    Type: Application
    Filed: October 18, 2011
    Publication date: February 27, 2014
    Inventors: Michael A. Murphy, Mitchell R. Malachowski
  • Publication number: 20130316984
    Abstract: The present invention relates to a liquid composition containing a polyorganosiloxane, a larvicide, which contains temephos, spinozad, dinetofuran, methopren, Bacillus thuringiensis, Bacillus thuringiensis israelensis, or Bacillus sphaericus, and at least 10 wt % of a water-immiscible synthetic organic solvent. It also relates to a method for preparing said composition comprising mixing the polyorganosiloxane, the larvicide, and optionally the further components; and to a method for controlling insects, wherein the said composition is applied on a water surface.
    Type: Application
    Filed: February 2, 2012
    Publication date: November 28, 2013
    Applicant: BASF SE
    Inventors: Claude Taranta, Helmut Mueller, Clark D. Klein, James W. Austin, Egon Weinmueller, Susanne Stutz
  • Patent number: 8546382
    Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: October 1, 2013
    Assignee: Children's Medical Center Corporation
    Inventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
  • Patent number: 8486919
    Abstract: The present invention provides a compound that has a high whitening effect and is excellent in safety and stability and provides an external preparation for skin comprising the same. The compound of the present invention is a 4-alkylresorcinol derivative represented by formula (1) or a salt thereof: wherein R1 is a branched or cyclic alkyl group of 3 to 7 carbon atoms or a linear alkyl group of 2 to 5 carbon atoms; R2 and R3 are each independently a hydrogen atom or a group represented by —P(O)(OR4)(OR5), and at least one of R2 and R3 is a group represented by —P(O)(OR4)(OR5); and R4 and R5 are each independently a hydrogen atom or a linear or branched alkyl group of 2 to 5 carbon atoms.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: July 16, 2013
    Assignee: Shiseido Company, Ltd.
    Inventors: Hirotada Fukunishi, Rikako Suzuki, Kiyoshi Sato, Masaru Suetsugu
  • Publication number: 20130136752
    Abstract: The present disclosure provides novel ophthalmic formulations for ocular administration comprising a pharmaceutically effective amount of a combretastatin, from 60% to 95% w/w pre-gelatinized starch, from 1% to 10% w/w hydrophilic matrix forming polymer, and from 0.2% to 5% lubricant.
    Type: Application
    Filed: August 17, 2012
    Publication date: May 30, 2013
    Applicant: OXIGENE, INC.
    Inventors: Suman Sharma, Bronwyn G. Siim
  • Publication number: 20130129814
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 23, 2013
    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventor: ABBOTT CARDIOVASCULAR SYSTEMS INC.
  • Publication number: 20130090371
    Abstract: The present invention generally relates to compositions and kits comprising a ?2-AR agonist and a modulator of a ?2-AR regulator gene, where the modulator of the ?2-AR regulator gene inhibits the internalization and/or degradation of the ?2-ad-renergic receptor (?2-AR). More specifically, the present invention relates to the use of an agonist of ?2-adrenergic receptor (?2-AR) and an agent which inhibits agonist induced ?2-adrenergic receptor (?2-AR) internalization and/or degradation in method for the treatment of a respiratory disorder in a subject.
    Type: Application
    Filed: April 20, 2011
    Publication date: April 11, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventor: Quan Lu
  • Publication number: 20130090311
    Abstract: Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described.
    Type: Application
    Filed: April 27, 2011
    Publication date: April 11, 2013
    Applicant: The Johns Hopkins University
    Inventors: Caren Laura Freel Meyers, Marie Webster
  • Publication number: 20130052173
    Abstract: A method for limiting the growth of microorganisms in a biomass that can he used for, or is the result of, the production of biofuels by treating said biomass with a compound selected from the group constituted by menadione, menadione derivatives and mixtures thereof.
    Type: Application
    Filed: July 2, 2010
    Publication date: February 28, 2013
    Inventor: Paolo Alberto Manzotti
  • Publication number: 20120322767
    Abstract: Compositions for pharmaceutical use are described, comprising bisphosphonates and vitamin D in high concentration, destined to the intramuscular and subcutaneous intermittent administration for treatment of bone and skeletal system diseases, particularly osteoporosis, and sensitive cancers. These formulations are characterized by the use of a lipid and phospholipid emulsion at high concentration, having optimal carrier and solvent power for both the pharmacologically active components.
    Type: Application
    Filed: November 25, 2010
    Publication date: December 20, 2012
    Inventor: Tiberio Bruzzese
  • Publication number: 20120316139
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also disclosed.
    Type: Application
    Filed: July 27, 2012
    Publication date: December 13, 2012
    Inventor: Basil RIGAS
  • Patent number: 8236820
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: August 7, 2012
    Inventor: Basil Rigas
  • Patent number: 8232261
    Abstract: The present invention provides a method of reducing phytotoxicity or plant injury at a crop plant locus caused by a herbicide application at the locus which method includes applying to the crop plant locus a chloronicotinyl insecticide before the herbicide application.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: July 31, 2012
    Assignee: Bayer CropScience LP
    Inventor: Michael R. Schwarz
  • Publication number: 20120138506
    Abstract: The invention relates a pharmaceutical composition comprising a combination of (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of selected conditions or diseases.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 7, 2012
    Inventors: Gary Michael Ksander, Randy Lee Webb
  • Publication number: 20120142641
    Abstract: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.
    Type: Application
    Filed: June 7, 2010
    Publication date: June 7, 2012
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Subramanian Venkatraman, Say Chye Joachim Loo
  • Publication number: 20120108548
    Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.
    Type: Application
    Filed: March 5, 2010
    Publication date: May 3, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITÄT DUISBURG-ESSEN, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Gal Bitan, Akila Shanmugam, Aleksey Lomakin, Thomas Schrader, Frank Gerrit Klarner, Peter Talbiersky, Jolanta Polkowska, Frank Bastkowski, Sharmistha Sinha, Sally Frautschy
  • Publication number: 20120108549
    Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.
    Type: Application
    Filed: April 15, 2010
    Publication date: May 3, 2012
    Inventors: Balaraman Kalyanaraman, Joy Joseph, Anumantha Kanthasamy
  • Publication number: 20120101067
    Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.
    Type: Application
    Filed: April 15, 2010
    Publication date: April 26, 2012
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
  • Patent number: 8153588
    Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: April 10, 2012
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: John Dietrich, Sverker Ljunghall, Sven Sjögren